Employees: 48
Size iX Biopharma (42C.SI) is a Singapore Health Care company (Pharmaceuticals: Major) with a market value of $387M, the 121st largest of 184 Singapore companies the cockpit tracks. Shares closed at S$0.46 on 18 Nov 2026.
Performance Over six months the shares gained 28.2%, against -23.1% for the median peer and -4.6% for the Singapore market (cap-weighted) — 2nd highest of 19 in its peer set.
Growth Revenue fell 11.8% over the last twelve months (peer median -2.8%); the operating margin is -139.5% (peer median -7.8%).
Valuation It trades at 71.6× enterprise value to sales against a peer median of 4.9× (3rd most expensive of 18).
Capital Return on invested capital runs 132.8 points below its cost of capital (10.6% WACC).
Next results Next results expected around 5 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|---|
| Revenue | n/a | S$6.85M | S$7.77M | S$5.96M | S$5.91M |
| Revenue growth | — | -12% | +30% | +1% | — |
| Gross profit | n/a | S$2.43M | S$2.04M | S$1.05M | S$2.32M |
| EBITDA | n/a | -S$8.83M | -S$5.43M | -S$6.63M | -S$9.71M |
| Net income | n/a | -S$7.99M | -S$10.1M | -S$10.8M | -S$9.62M |
| Free cash flow | n/a | -S$8.07M | -S$4.59M | -S$7.09M | -S$8.63M |
| Capital expenditure | n/a | S$117,000 | S$201,000 | S$285,000 | S$695,000 |
| Total debt | S$3.44M | S$5.80M | S$5.90M | S$5.20M | S$4.34M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 42C.SI | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -13.3% | -12.7% | 9th lowest of 20 |
| 6-month return | +28.2% | -23.1% | 2nd highest of 19 |
| Distance from 52-week high | -27.2% | -44.6% | 5th highest of 21 |
| Revenue growth (TTM) | -11.8% | -2.8% | 8th lowest of 18 |
| Operating margin | -139.5% | -7.8% | 6th lowest of 19 |
| EV / Sales | 71.6× | 4.9× | 3rd most expensive of 18 |
| ROIC minus cost of capital | -132.8 pp | -5.4 pp | 3rd lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| iX Biopharma 42C.SI | Singapore | $387M | +28% | -12% | -140% | 71.6× | n/a | n/a |
| Shukra Pharmaceuticals SHUKRAPHAR.NS | India | $387M | n/a | +222% | 54% | 32.0× | n/a | n/a |
| Gansu Longshenrongfa Pharmaceutical Industry 300534.SZ | China | $386M | -2% | -21% | 8% | 3.7× | 20.9% | +28.2% |
| Avalo Therapeutics AVTX | United States | $387M | -59% | -69% | -161,961% | n/a | n/a | n/a |
| SanBio 4592.T | Japan | $386M | -55% | n/a | n/a | n/a | n/a | n/a |
| Anhui Sunhere Pharmaceutical Excipients 300452.SZ | China | $388M | -17% | +9% | 19% | 2.2× | -5.5% | +12.2% |
| Lifecome Biochemistry 002868.SZ | China | $384M | -54% | -23% | -3% | 6.2× | n/a | n/a |
| Heartseed 219A.T | Japan | $392M | +53% | +197% | 9% | 21.9× | 46.5% | +73.2% |
| JCR Pharmaceuticals 4552.T | Japan | $379M | -5% | +3% | -14% | 2.9× | n/a | n/a |
| Opus Genetics IRD | United States | $379M | -22% | -46% | -778% | 41.2× | n/a | n/a |
| Jiangxi Synergy Pharmaceutical 300636.SZ | China | $398M | -13% | -3% | 2% | 3.4× | 14.9% | +13.7% |
| Jiangsu Bioperfectus Technologies 688399.SS | China | $374M | -51% | -8% | -23% | 4.4× | n/a | n/a |
| Puma Biotechnology PBYI | United States | $373M | +3% | +9% | 11% | 1.2× | 0.1% | +0.3% |
| ARS Pharmaceuticals SPRY | United States | $371M | -53% | -14% | -162% | 2.9× | n/a | n/a |
| Tiansheng Pharmaceutical 002872.SZ | China | $371M | -1% | -1% | -13% | 4.9× | 22.2% | -15.7% |
| Shandong Sinobioway Biomedicine 002581.SZ | China | $405M | -24% | +91% | -65% | 7.9× | n/a | n/a |
| MapLight Therapeutics MPLT | United States | $370M | -76% | n/a | n/a | n/a | n/a | n/a |
| Beijing Centergate Technologies (Holding) 000931.SZ | China | $406M | -18% | -16% | 2% | 1.9× | 9.2% | +6.7% |
| Lumosa Therapeutics 6535.TWO | Taiwan | $406M | -37% | -25% | -803% | 399.1× | n/a | n/a |
| 6467 6467.TW | Taiwan | $368M | n/a | n/a | -2,618% | 1,407.9× | n/a | n/a |
| Guangdong Lifestrong Pharmacy 301111.SZ | China | $368M | -33% | +7% | -2% | 7.2× | n/a | n/a |